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June 24, 2008:2442–5imely access to primary PCI by establishing regionalized networks
f hospitals for STEMI.
In this context, the present analysis adds important new
nformation to the literature. Our findings suggest shorter total
oor-to-balloon times in transfer patients during the interven-
ng few years (i.e., 152 min vs. 180 min). However, we also
ound that many patients still have marked delays in total
oor-to-balloon times and that few reach the benchmark
stablished by national guidelines. Compared with the previous
nalysis, total door-to-balloon times were shorter because of
ore rapid door-to-door times (109 min vs. 120 min) and PCI
ospital door-to-balloon times (38 min vs. 53 min). Of course,
ny direct comparisons between the present and previous
nalyses should be done with caution, owing to the involvement
f different hospitals and types of patients between registries.
he present analysis, for example, included more nonurban
ospitals as well as patients with cardiogenic shock. Finally, it
s important to note that these hospitals participated voluntarily
n the CathPCI registry, a national quality improvement regis-
ry. These hospitals therefore may present a “best”-case scenario
or transfer patients.
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studies, our results align well with those of Narducci et al. (1),
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infarction. N Engl J Med 2003;349:733–42.Letters to the Editorelomerase-Positive Neutrophils:
laque “Survivors” and Restenosis
arducci et al. (1) recently demonstrated high telomerase
ctivity in polymorphonuclear neutrophilic leukocytes (PMNs)
erived from plaques in patients with unstable angina. In
ontrast, PMNs from stable coronary plaques and peripheral
lood samples had minimal telomerase activity. The authors’
nalysis relied on a novel, though indirect, method of acquiring
laque PMNs; specifically, they studied cells isolated by wash-
ng angioplasty balloons. Immunohistochemical techniques
onfirmed that 90% of adherent cells were neutrophils. We
ave previously reported a different strategy for analyzing
laque telomerase activity (2). Using tissue acquired from 23
atients undergoing directional coronary atherectomy (DCA),
e found that 8 of 23 (35%) were positive for telomerase (2).
ll but 1 of these patients presented with an acute coronary
yndrome. Although the quantification of the telomeric repeat
mplification protocol (TRAP) was performed differently in theho found high telomerase activity in 6 of 20 (30%) of their
atients with unstable angina. Because DCA samples contain
ells other than PMNs, such as vascular smooth muscle
ells, endothelial cells, and macrophages, the similar rates of
RAP positivity would suggest that PMNs are the major source
f telomerase in the unstable plaque. However, additional
tudies using in situ assays are warranted before this conclusion
s firmly established. The infiltration of coronary plaques by
MNs with persistent or reactivated telomerase could promote
n exaggerated local inflammatory response and lead to plaque
nstability. It is also plausible that PMN-derived telomerase
ctivity promotes restenosis (3). Of note in this regard, we
ound that patients with telomerase-positive DCA tissue were
ore likely to experience clinical or angiographic evidence of
estenosis (2).
Thus, using 2 different strategies, 30% to 35% of unstable
oronary plaques have “survivors” or telomerase-positive cells (1,2).
arducci et al. (1) provide strong support that these cells are
redominantly PMNs. Their study could provide a novel strategy
or identifying patients at increased risk for adverse events,
ncluding restenosis.
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eply
e welcome the data provided by Dr. Sane, who found telomerase
ctivation in cells from coronary atherectomy specimens (1). It is
orth noting, however, that we assessed telomerase activation
pecifically in neutrophils from atherosclerotic plaques (2). We
ever found telomerase activation in neutrophils from stable
atients, although we found it in about one-third of unstable
atients, particularly in those with a recent episode of rest angina.
hus, our findings suggest that telomerase activation in neutro-
hils may be important in the early phases of coronary instability.
n contrast, Dr. Sane found telomerase activation in about one-
hird of stable patients in cells obtained from coronary atherec-
omy specimens. Interestingly, they found a correlation between
elomerase activation and restenosis rate, suggesting that telomer-
se reactivation in cells, which are not necessarily neutrophils,
ontained in stable atherosclerotic plaque may be important in the
echanism of restenosis. Therefore, the similar prevalence of
elomerase activation in the 2 studies is probably just a coincidence.
evertheless, both studies underscore the biological relevance of
elomerase activation in the microenvironment of the atheroscle-
otic plaque and its different role in different clinical settings. In
ddition, both studies raise a number of unanswered questions.
hy does telomerase activation occur only in a subset of patients?
hat are the molecular pathways leading to telomerase activation?
hat is the relationship between neutrophil telomerase activation
n the plaque and levels of neutrophil activation markers in
eripheral blood? What is the impact of telomerase activation in
he microenvironment of the atherosclerotic plaque on the out-
ome in different clinical settings? Further studies are warranted to
ddress these issues.
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ocal Amyloidosis as a
ossible Component of the Atrial
emodeling Accompanying Trial
n their extensive state-of-the-art paper on the clinical implica-
ions for atrial fibrillation of structural and functional remodeling
f the left atrium, Casaclang-Verzosa et al. (1) do not mention an
mportant structural aspect of the process, namely, intra-atrial
myloid deposition accompanying long-term atrial fibrillation
AF). In the last few years, 2 separate research groups have
rovided evidence that, in humans, longstanding AF is associated
ith intra-atrial deposition of amyloid, particularly in women with
alvular atrial fibrillation (2,3). Amyloid deposits appear to occur
referentially in the left atrium (3). An immunohistochemical
tudy showed that similar deposits were invariably immunoreactive
or atrial natriuretic peptide (ANP) (2). These observations have
rompted the hypothesis that AF-related overproduction of ANP
eads to localized amyloidogenesis and deposition, which in turn
ugments conduction heterogeneity, helping to perpetuate AF
and thereby stimulating further ANP production in a paracrine
oop) (4). In this view, atrial amyloid deposition could be consid-
red to be a further negative consequence of the neurohormonal
isturbances elegantly discussed by the authors of the article. In
ny case, we believe amyloid deposition deserves serious con-
ideration as a potential player in the complex interplay between
natomical and electrical left atrial remodeling, together with
he other pathophysiological changes (stressors) discussed by
he authors, such as interstitial fibrosis, myocyte hypertrophy,
on channel alterations, inflammatory reactions, and so on.
lthough no pharmacological treatment is currently available to
emove the amyloid deposits, much research is being carried out
n this field (5).
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